TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Geoffrey R. Oxnard(Dana-Farber Cancer Institute), J.C.-H. Yang(National Taiwan University Hospital), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Seung‐Whan Kim(Ulsan College), Hideo Saka(Nagoya Medical Center), Leora Horn(Vanderbilt University), Kōichi Goto(National Cancer Center Hospital East), Yuichiro Ohe, Helen Mann(AstraZeneca (United Kingdom)), Kenneth S. Thress(AstraZeneca (United States)), Melanie M. Frigault(AstraZeneca (United States)), Karthick Vishwanathan(AstraZeneca (United States)), Dana Ghiorghiu(AstraZeneca (United Kingdom)), Suresh S. Ramalingam(Emory University), Myung‐Ju Ahn(Samsung Medical Center)
Cited by 441
Abstract
Related Papers
No related papers found
Powered by citation graph analysis